Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Pyrotinib|DRUG: nab-Paclitaxel|DRUG: Trastuzumab|DRUG: EC chemotherapy|PROCEDURE: Surgery
Sponsor: Shanghai Jiao Tong University School of Medicine
Collaborators: Jiangsu HengRui Medicine Co., Ltd.